XLVvsXBIETF Comparison
VS
State Street Health Care Select Sector SPDR ETF (XLV) and State Street SPDR S&P Biotech ETF (XBI) belong to the same industry segment: US Health Care. XLV's top 2 sector exposures are Healthcare and Consumer Non-Cyclicals. In contrast, XBI's top sector exposures are Healthcare and Finance. XLV is less expensive with a Total Expense Ratio (TER) of 0.08%, versus 0.35% for XBI. XLV is up 14.43% year-to-date (YTD) with +$882M in YTD flows. XBI performs better with 39.08% YTD performance, and +$682M in YTD flows. Run a side-by-side ETF comparison of XLV and XBI below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
XLV vs XBI performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 08/19/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | XLV XBI | +10.28%+12.32% | +19.78%+33.80% | +14.43%+39.08% | +30.69%+91.73% | +38.16%+117.37% | +40.63%+43.79% |
| Flows | XLV XBI | +$273M+$51M | +$692M+$1.20B | +$882M+$682M | +$2.97B+$1.29B | -$4.91B-$224M | +$2.84B+$1.72B |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | XLV XBI | +19.54%+31.14% | +15.87%+27.54% | +14.61%+28.11% | +15.10%+32.92% |
| Max drawdown | XLV XBI | -3.83%-10.46% | -10.51%-10.46% | -17.05%-32.94% | -17.05%-54.07% |
| Max drawdown duration | XLV XBI | 20d40d | 116d40d | 444d331d | 444d1685d |
Trading data
XLV | XBI | |
Last sale 8/19/2026 at 1:30 PM | $175.68 | $169.55 |
| Previous close 08/19/2026 | $169.73 | $160.11 |
| Consolidated volume 08/19/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of July 31, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
XLV | XBI | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 8/19/2026 at 1:30 PM
Live
Closed
XLV | XBI | |
|---|---|---|
| Last price | $175.68 | $169.55 |
| 1D performance | +3.51% | +5.90% |
| AuM | $45.88 B | $11.58 B |
| E/R | 0.08% | 0.35% |
Characteristics
XLV | XBI | |
|---|---|---|
| Management strategy | Passive | Passive |
| Provider | State Street Investment Management | State Street Investment Management |
| Benchmark | S&P Health Care Select Sector Index | S&P Biotechnology Select Industry Index |
| N° of holdings | 59 | 150 |
| Asset class | Equities | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | December 16, 1998 | January 31, 2006 |
| ESG | No | No |
Advertisement
Exposure
Countries
XLV
USA
97.92%
Other
2.08%
XBI
USA
95.06%
Other
4.94%
Sectors
XLV
Healthcare
97.73%
Other
2.27%
XBI
Healthcare
99.03%
Other
0.97%
Advertisement
Diversification
XLV
Total weight of top 15 holdings out of 15
72.82%
XBI
Total weight of top 15 holdings out of 15
19.19%
Top 15 holdings
Data as of June 30, 2026
XLV
Eli Lilly & Co.
16.57%
Johnson & Johnson
10.68%
AbbVie, Inc.
7.76%
UnitedHealth Group, Inc.
6.59%
Merck & Co., Inc.
5.54%
Amgen, Inc.
3.41%
Thermo Fisher Scientific, Inc.
3.25%
Abbott Laboratories
2.76%
Gilead Sciences, Inc.
2.74%
Intuitive Surgical, Inc.
2.46%
Pfizer Inc.
2.40%
CVS Health Corp.
2.31%
Vertex Pharmaceuticals, Inc.
2.20%
Danaher Corp.
2.10%
Bristol Myers Squibb Co.
2.05%
XBI
Apogee Therapeutics, Inc.
1.48%
Moderna, Inc.
1.41%
Twist Bioscience Corp.
1.40%
Oruka Therapeutics, Inc.
1.37%
Kymera Therapeutics, Inc.
1.35%
Viking Therapeutics, Inc.
1.30%
Praxis Precision Medicines, Inc.
1.29%
Erasca, Inc.
1.27%
Revolution Medicines, Inc.
1.20%
Rhythm Pharmaceuticals, Inc.
1.20%
CG Oncology, Inc.
1.20%
SELLAS Life Sciences Group, Inc.
1.19%
Vaxcyte, Inc.
1.18%
Dianthus Therapeutics, Inc.
1.18%
Cytokinetics, Inc.
1.17%
Frequently asked questions about XLV and XBI
How have the XLV and XBI ETFs performed in 2026?
As of August 19, 2026, XLV is up 14.43% year-to-date (YTD), while XBI has returned 39.08%. That puts XBI better performer ahead so far this year.
Which ETF is attracting more investor money: XLV or XBI?
Year-to-date, the XLV ETF saw +$882M in flows, compared to +$682M for XBI.
Which ETF is more volatile: XLV or XBI?
Over the past year, XLV had a volatility of 15.87%, while XBI experienced 27.54%.
Which ETF is bigger: XLV or XBI?
As of August 19, 2026, XLV holds $45.88 B in assets under management (AUM), while XBI manages $11.58 B.
What sectors do the XLV and XBI ETFs invest in?
XLV leans toward sectors like Healthcare. Meanwhile, XBI focuses on Healthcare.
What are the top holdings of the XLV ETF and XBI ETF?
XLV top holdings include Eli Lilly & Co., Johnson & Johnson and AbbVie, Inc.. XBI holds in its top three: Apogee Therapeutics, Inc., Moderna, Inc. and Twist Bioscience Corp..
Which ETF is more diversified: XLV or XBI?
XLV holds 59 securities with 72.82% of its assets in the top 15. XBI has 153 securities and a top 15 weight of 19.19%.
Advertisement
Latest news about XLV & XBI
ETF Model Portfolios: The Cockroach Portfolio
March 20, 2026
XLV
ETF Central's Guide to Defensive Sector Investing
March 13, 2026
XLV
Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities
September 18, 2025
XBI
Are Biotechnology ETFs In the Midst of a Comeback?
August 20, 2025
XBI
Advertisement
Chinese Artificial Intelligence (AI) DeepSeek: ETF Winners & Losers
January 27, 2025
XLV
Chinese Artificial Intelligence (AI) DeepSeek: ETF Winners & Losers
January 27, 2025
XLV
Investing in Sector ETFs: Consumer Staples, Healthcare, & Utilities
August 21, 2024
XLV
Healthcare Stocks Drop on Medicare Payment Rate Surprise
April 8, 2024
XLV
Advertisement
